Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Impact of oral galenic formulations of Lactobacillus salivarius on probiotic survival and interactions with microbiota in human in vitro gut models
in Beneficial MicrobesSearch for other papers by M.E. Arnal in
Current site
Google Scholar
Search for other papers by S. Denis in
Current site
Google Scholar
Search for other papers by O. Uriot in
Current site
Google Scholar
Search for other papers by C. Lambert in
Current site
Google Scholar
Search for other papers by S. Holowacz in
Current site
Google Scholar
Search for other papers by F. Paul in
Current site
Google Scholar
Search for other papers by S. Kuylle in
Current site
Google Scholar
Search for other papers by B. Pereira in
Current site
Google Scholar
Search for other papers by M. Alric in
Current site
Google Scholar
Search for other papers by S. Blanquet-Diot in
Current site
Google Scholar
Health benefits of probiotics in humans essentially depend on their ability to survive during gastrointestinal (GI) transit and to modulate gut microbiota. To date, there is few data on the impact of galenic formulations of probiotics on these parameters. Even if clinical studies remain the gold standard to evaluate the efficacy of galenic forms, they stay hampered by technical, ethical and cost reasons. As an alternative approach, we used two complementary in vitro models of the human gut, the TNO gastrointestinal (TIM-1) model and the Artificial Colon (ARCOL), to study the effect of three oral formulations of a Lactobacillus salivarius strain (powder, capsule and sustained-release tablet) on its viability and interactions with gut microbiota. In the TIM-1 stomach, no or low numbers of bacteria were respectively released from the capsule and tablet, confirming their gastro-resistance. The capsule was disintegrated in the jejunum on average 76 min after administration while the core of sustained-release tablet was still intact at the end of digestion. Viability in TIM-1 was significantly influenced by the galenic form with survival percentages of 0.003±0.004%, 2.8±0.6% and 17.0±1.8% (n=3) for powder, capsule and tablet, respectively. In the ARCOL, the survival of the strain tended to be higher in the post-treatment phase with the tablet compared to capsule, but gut microbiota composition and activity were not differently modulated by the two formulations. In conclusion, the sustained-release tablet emerged as the formulation that most effectively preserved viability of the tested strain during GI passage. This study highlights the usefulness of in vitro gut models for the pre-screening of probiotic pharmaceutical forms. Their use could also easily be extended to the evaluation of the effects of food matrices and age on probiotic survival and activity during GI transit.
-
Atia, A., Gomaa, A., Fernandez, B., Subirade, M. and Fliss, I., 2018. Study and understanding behavior of alginate-inulin synbiotics beads for protection and delivery of antimicrobial-producing probiotics in colonic simulated conditions. Probiotics Antimicrobial Proteins 10: 157-167. https://doi.org/10.1007/s12602-017-9355-x
-
Azad, M.A.K., Sarker, M., Li, T. and Yin, J., 2018. Probiotic species in the modulation of gut microbiota: an overview. Biomed Research International 2018: 9478630. https://doi.org/10.1155/2018/9478630
-
Barache, N., Ladjouzi, R., Belguesmia, Y., Bendali, F. and Drider, D., 2020. Abundance of Lactobacillus plantarum strains with beneficial attributes in blackberries (Rubus sp.), fresh figs (Ficus carica), and prickly pears (Opuntia ficus-indica) grown and harvested in Algeria. Probiotics Antimicrobial Proteins 12: 1514-1523. https://doi.org/10.1007/s12602-020-09632-z
-
Begley, M., Hill, C. and Gahan, C.G.M., 2006. Bile salt hydrolase activity in probiotics. Applied and Environmental Microbiology 72: 1729-1738. https://doi.org/10.1128/AEM.72.3.1729-1738.2006
-
Blanquet-Diot, S., Denis, S., Chalancon, S., Chaira, F., Cardot, J.-M., Alric, M., 2012. Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans. Pharmaceutical Research 29: 1444-1453. https://doi.org/10.1007/s11095-011-0620-5
-
Bussolo de Souza, C., Roeselers, G., Troost, F., Jonkers, D., Koenen, M.E. and Venema, K., 2014. Prebiotic effects of cassava bagasse in TNO’s in vitro model of the colon in lean versus obese microbiota. Journal of Functional Foods 11: 210-220. https://doi.org/10.1016/j.jff.2014.09.019
-
Campana, R., Van Hemert, S. and Baffone, W., 2017. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathogens 9: 12. https://doi.org/10.1186/s13099-017-0162-4
-
Chaves, B.D., Brashears, M.M. and Nightingale, K.K., 2017. Applications and safety considerations of Lactobacillus salivarius as a probiotic in animal and human health. Journal of Applied Microbiology 123: 18-28. https://doi.org/10.1111/jam.13438
-
Cheow, W.S., Kiew, T.Y. and Hadinoto, K., 2014. Controlled release of Lactobacillus rhamnosus biofilm probiotics from alginate-locust bean gum microcapsules. Carbohydrate Polymers 103: 587-595. https://doi.org/10.1016/j.carbpol.2014.01.036
-
Cole, E.T., Scott, R.A., Connor, A.L., Wilding, I.R., Petereit, H.U., Schminke, C., Beckert, T. and Cadé, D., 2002. Enteric coated HPMC capsules designed to achieve intestinal targeting. International Journal of Pharmaceutics 231: 83-95. https://doi.org/10.1016/s0378-5173(01)00871-7
-
Cordonnier, C., Thévenot, J., Etienne-Mesmin, L., Denis, S., Alric, M., Livrelli, V. and Blanquet-Diot, S., 2015. Dynamic in vitro models of the human gastrointestinal tract as relevant tools to assess the survival of probiotic strains and their interactions with gut microbiota. Microorganisms 3: 725-745. https://doi.org/10.3390/microorganisms3040725
-
Denis, S., Sayd, T., Georges, A., Chambon, C., Chalancon, S., Santé-Lhoutellier, V. and Blanquet-Diot, S., 2016. Digestion of cooked meat proteins is slightly affected by age as assessed using the dynamic gastrointestinal TIM model and mass spectrometry. Food Functions 7: 2682-2691. https://doi.org/10.1039/c6fo00120c
-
Ding, W.K. and Shah, N.P., 2009. An improved method of microencapsulation of probiotic bacteria for their stability in acidic and bile conditions during storage. Journal of Food Science 74: M53-61. https://doi.org/10.1111/j.1750-3841.2008.01030.x
-
Drago, L., Toscano, M., De Vecchi, E., Piconi, S. and Iemoli, E., 2012. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. Journal of Clinical Gastroenterology 46, Suppl.: S56-63. https://doi.org/10.1097/MCG.0b013e318265ef38
-
Eiberger, I., Bley, H., Molimard, P., Maathuis, A. and Venema, K., 2011. Evaluation of the appropriate galenical technology for the site specific delivery of probiotic bacteria. In: Proceedings of Vitagora. Vitagora, Dijon, France, p. 7.
'Evaluation of the appropriate galenical technology for the site specific delivery of probiotic bacteria ', () 7.
-
Fang, F., Li, Y., Bumann, M., Raftis, E.J., Casey, P.G., Cooney, J.C., Walsh, M.A. and O’Toole, P.W., 2009. Allelic variation of bile salt hydrolase genes in Lactobacillus salivarius does not determine bile resistance levels. Journal of Bacteriology 191: 5743-5757. https://doi.org/10.1128/JB.00506-09
-
Food and Agricultural Organization of the United Nations and World Health Organization (FAO/WHO), 2002. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. FAO/WHO, Rome/Geneva, Italy/Switzerland.
-
Fuochi, V., Petronio, G.P., Lissandrello, E., and Furneri, P.M., 2015. Evaluation of resistance to low pH and bile salts of human Lactobacillus spp. isolates. International Journal of Immunopathology and Pharmacology 28: 426-433. https://doi.org/10.1177/0394632015590948
-
Gately, N.M. and Kennedy, J.E., 2017. The development of a melt-extruded shellac carrier for the targeted delivery of probiotics to the colon. Pharmaceutics 9: 38. https://doi.org/10.3390/pharmaceutics9040038
-
Govender, M., Choonara, Y.E., Van Vuuren, S., Kumar, P., Du Toit, L.C. and Pillay, V., 2015. A gastro-resistant ovalbumin bi-layered mini-tablet-in-tablet system for the delivery of Lactobacillus acidophilus probiotic to simulated human intestinal and colon conditions. Journal of Pharmacy and Pharmacology 67: 939-950. https://doi.org/10.1111/jphp.12389
-
He, M. and Shi, B., 2017. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell and Bioscience 7: 54. https://doi.org/10.1186/s13578-017-0183-1
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
-
Holowacz, S., Blondeau, C., Guinobert, I., Guilbot, A., Hidalgo, S. and Bisson, J.F., 2018. Lactobacillus salivarius LA307 and Lactobacillus rhamnosus LA305 attenuate skin inflammation in mice. Beneficial Microbes 9: 299-309. https://doi.org/10.3920/BM2017.0084
-
Hou, Q., Zhao, F., Liu, W., Lv, R., Khine, W.W.T., Han, J., Sun, Z., Lee, Y.-K. and Zhang, H., 2020. Probiotic-directed modulation of gut microbiota is basal microbiome dependent. Gut Microbes 12: 1736974. https://doi.org/10.1080/19490976.2020.1736974
-
Klingberg, T.D. and Budde, B.B., 2006. The survival and persistence in the human gastrointestinal tract of five potential probiotic lactobacilli consumed as freeze-dried cultures or as probiotic sausage. International Journal of Food Microbiology 109: 157-159. https://doi.org/10.1016/j.ijfoodmicro.2006.01.014
-
Larsen, N., Vogensen, F.K., Gøbel, R.J., Michaelsen, K.F., Forssten, S.D., Lahtinen, S.J., Jakobsen, M., 2013. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clinical Nutrition 32: 935-940. https://doi.org/10.1016/j.clnu.2013.02.007
-
Lv, L.-X., Yan, R., Shi, H.-Y., Shi, D., Fang, D.-Q., Jiang, H.-Y., Wu, W.-R., Guo, F.-F., Jiang, X.-W., Gu, S.-L., Chen, Y.-B., Yao, J. and Li, L.-J., 2017. Integrated transcriptomic and proteomic analysis of the bile stress response in probiotic Lactobacillus salivarius LI01. Journal of Proteomics 150: 216-229. https://doi.org/10.1016/j.jprot.2016.08.021
-
Marteau, P., Minekus, M., Havenaar, R. and Huis in’t Veld, J.H., 1997. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effects of bile. Journal of Dairy Science 80: 1031-1037. https://doi.org/10.3168/jds.S0022-0302(97)76027-2
-
Marzorati, M., Possemiers, S., Verhelst, A., Cadé, D., Madit, N. and Van de Wiele, T., 2015. A novel hypromellose capsule, with acid resistance properties, permits the targeted delivery of acid-sensitive products to the intestine. LWT – Food Science and Technology 60: 544-551. https://doi.org/10.1016/j.lwt.2014.08.040
-
Messaoudi, S., Manai, M., Kergourlay, G., Prévost, H., Connil, N., Chobert, J.-M., Dousset, X., 2013. Lactobacillus salivarius: bacteriocin and probiotic activity. Food Microbiology 36: 296-304. https://doi.org/10.1016/j.fm.2013.05.010
-
Minelli, E.B. and Benini, A., 2008. Relationship between number of bacteria and their probiotic effects. Microbial Ecology in Health and Disease 20: 180-183. https://doi.org/10.1080/08910600802408095
-
Park, W., 2018. Gut microbiomes and their metabolites shape human and animal health. Journal of Microbiology 56: 151-153. https://doi.org/10.1007/s12275-018-0577-8
-
Patrignani, F., Siroli, L., Parolin, C., Serrazanetti, D.I., Vitali, B. and Lanciotti, R., 2019. Use of Lactobacillus crispatus to produce a probiotic cheese as potential gender food for preventing gynaecological infections. PLoS ONE 14: e0208906. https://doi.org/10.1371/journal.pone.0208906
-
Pereira, F.C. and Berry, D., 2017. Microbial nutrient niches in the gut. Environmental Microbiology 19: 1366-1378. https://doi.org/10.1111/1462-2920.13659
-
Plaza-Diaz, J., Ruiz-Ojeda, F.J., Gil-Campos, M. and Gil, A., 2019. Mechanisms of action of probiotics. Advanced Nutrition 10: S49-S66. https://doi.org/10.1093/advances/nmy063
-
Ribnicky, D.M., Roopchand, D.E., Oren, A., Grace, M., Poulev, A., Lila, M.A., Havenaar, R. and Raskin, I., 2014. Effects of a high fat meal matrix and protein complexation on the bioaccessibility of blueberry anthocyanins using the TNO gastrointestinal model (TIM-1). Food Chemistry 142: 349-357. https://doi.org/10.1016/j.foodchem.2013.07.073
-
Riboulet-Bisson, E., Sturme, M.H.J., Jeffery, I.B., O’Donnell, M.M., Neville, B.A., Forde, B.M., Claesson, M.J., Harris, H., Gardiner, G.E., Casey, P.G., Lawlor, P.G., O’Toole, P.W. and Ross, R.P., 2012. Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota. PLoS ONE 7: e31113. https://doi.org/10.1371/journal.pone.0031113
-
Roussel, C., Cordonnier, C., Galia, W., Le Goff, O., Thévenot, J., Chalancon, S., Alric, M., Thevenot-Sergentet, D., Leriche, F., Van de Wiele, T., Livrelli, V. and Blanquet-Diot, S., 2016. Increased EHEC survival and virulence gene expression indicate an enhanced pathogenicity upon simulated pediatric gastrointestinal conditions. Pediatric Research 80: 734-743. https://doi.org/10.1038/pr.2016.144
-
Sanhueza, E., Paredes-Osses, E., González, C.L. and García, A., 2015. Effect of pH in the survival of Lactobacillus salivarius strain UCO_979C wild type and the pH acid acclimated variant. Electronic Journal of Biotechnology 18: 343-346. https://doi.org/10.1016/j.ejbt.2015.06.005
-
Sniffen, J.C., McFarland, L.V., Evans, C.T. and Goldstein, E.J.C., 2018. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS ONE 13: e0209205. https://doi.org/10.1371/journal.pone.0209205
-
Soares, M.B., Martinez, R.C.R., Pereira, E.P.R., Balthazar, C.F., Cruz, A.G., Ranadheera, C.S. and Sant’Ana, A.S., 2019. The resistance of Bacillus, Bifidobacterium, and Lactobacillus strains with claimed probiotic properties in different food matrices exposed to simulated gastrointestinal tract conditions. Food Research International 125: 108542. https://doi.org/10.1016/j.foodres.2019.108542
-
Surono, I., Verhoeven, J., Verbruggen, S. and Venema, K., 2018. Microencapsulation increases survival of the probiotic Lactobacillus plantarum IS-10506, but not Enterococcus faecium IS-27526 in a dynamic, computer-controlled in vitro model of the upper gastrointestinal tract. Journal of Applied Microbiology 124: 1604-1609. https://doi.org/10.1111/jam.13740
-
Thévenot, J., Cordonnier, C., Rougeron, A., Le Goff, O., Nguyen, H.T.T., Denis, S., Alric, M., Livrelli, V. and Blanquet-Diot, S., 2015. Enterohemorrhagic Escherichia coli infection has donor-dependent effect on human gut microbiota and may be antagonized by probiotic yeast during interaction with Peyer’s patches. Applied Microbiology and Biotechnology 99: 9097-9110. https://doi.org/10.1007/s00253-015-6704-0
-
Uriot, O., Galia, W., Awussi, A.A., Perrin, C., Denis, S., Chalancon, S., Lorson, E., Poirson, C., Junjua, M., Le Roux, Y., Alric, M., Dary, A., Blanquet-Diot, S. and Roussel, Y., 2016. Use of the dynamic gastro-intestinal model TIM to explore the survival of the yogurt bacterium Streptococcus thermophilus and the metabolic activities induced in the simulated human gut. Food Microbiology 53: 18-29. https://doi.org/10.1016/j.fm.2015.05.007
-
Van den Abbeele, P., Roos, S., Eeckhaut, V., MacKenzie, D.A., Derde, M., Verstraete, W., Marzorati, M., Possemiers, S., Vanhoecke, B., Van Immerseel, F. and Van de Wiele, T., 2012. Incorporating a mucosal environment in a dynamic gut model results in a more representative colonization by lactobacilli. Microbial Biotechnology 5: 106-115. https://doi.org/10.1111/j.1751-7915.2011.00308.x
-
Venema, K., Verhoeven, J., Beckman, C. and Keller, D., 2020. Survival of a probiotic-containing product using capsule-within-capsule technology in an in vitro model of the stomach and small intestine (TIM-1). Beneficial Microbes 11: 403-409. https://doi.org/10.3920/BM2019.0209
-
Venema, K., Verhoeven, J., Verbruggen, S., Espinosa, L. and Courau, S., 2019. Probiotic survival during a multi-layered tablet development as tested in a dynamic, computer-controlled in vitro model of the stomach and small intestine (TIM-1). Letters in Applied Microbiology 69: 325-332. https://doi.org/10.1111/lam.13211
-
Vijaya Kumar, B., Vijayendra, S.V.N. and Reddy, O.V.S., 2015. Trends in dairy and non-dairy probiotic products – a review. Journal of Food Science and Technology 52: 6112-6124. https://doi.org/10.1007/s13197-015-1795-2
-
Villena, M.J.M., Lara-Villoslada, F., Martínez, M.A.R. and Hernández, M.E.M., 2015. Development of gastro-resistant tablets for the protection and intestinal delivery of Lactobacillus fermentum CECT 5716. International Journal of Pharmaceutics 487: 314-319. https://doi.org/10.1016/j.ijpharm.2015.03.078
-
Wang, G., Li, D., Ma, X., An, H., Zhai, Z., Ren, F. and Hao, Y., 2015. Functional role of oppA encoding an oligopeptide-binding protein from Lactobacillus salivarius Ren in bile tolerance. Journal of Industrial Microbiology and Biotechnology 42: 1167-1174. https://doi.org/10.1007/s10295-015-1634-5
-
Wang, Z., Zeng, X., Mo, Y., Smith, K., Guo, Y. and Lin, J., 2012. Identification and characterization of a bile salt hydrolase from Lactobacillus salivarius for development of novel alternatives to antibiotic growth promoters. Applied and Environmental Microbiology 78: 8795-8802. https://doi.org/10.1128/AEM.02519-12
-
Wexler, A.G. and Goodman, A.L., 2017. An insider’s perspective: Bacteroides as a window into the microbiome. Nature Microbiology 2: 17026. https://doi.org/10.1038/nmicrobiol.2017.26
-
Wexler, H.M., 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clinical Microbiology Reviews 20: 593-621. https://doi.org/10.1128/CMR.00008-07
-
Yang, J., Wang, C., Huang, K., Zhang, M., Wang, J. and Pan, X., 2020. Compound Lactobacillus sp. administration ameliorates stress and body growth through gut microbiota optimization on weaning piglets. Applied Microbiology and Biotechnology 104: 6749-6765. https://doi.org/10.1007/s00253-020-10727-4
Supplementary Materials
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 0 | 0 | 0 |
| Gesamttextansichten | 633 | 217 | 27 |
| PDF-Downloads | 540 | 179 | 15 |
Impact of oral galenic formulations of Lactobacillus salivarius on probiotic survival and interactions with microbiota in human in vitro gut models
in Beneficial MicrobesSearch for other papers by M.E. Arnal in
Current site
Google Scholar
PubMed
Search for other papers by S. Denis in
Current site
Google Scholar
PubMed
Search for other papers by O. Uriot in
Current site
Google Scholar
PubMed
Search for other papers by C. Lambert in
Current site
Google Scholar
PubMed
Search for other papers by S. Holowacz in
Current site
Google Scholar
PubMed
Search for other papers by F. Paul in
Current site
Google Scholar
PubMed
Search for other papers by S. Kuylle in
Current site
Google Scholar
PubMed
Search for other papers by B. Pereira in
Current site
Google Scholar
PubMed
Search for other papers by M. Alric in
Current site
Google Scholar
PubMed
Search for other papers by S. Blanquet-Diot in
Current site
Google Scholar
PubMed
Health benefits of probiotics in humans essentially depend on their ability to survive during gastrointestinal (GI) transit and to modulate gut microbiota. To date, there is few data on the impact of galenic formulations of probiotics on these parameters. Even if clinical studies remain the gold standard to evaluate the efficacy of galenic forms, they stay hampered by technical, ethical and cost reasons. As an alternative approach, we used two complementary in vitro models of the human gut, the TNO gastrointestinal (TIM-1) model and the Artificial Colon (ARCOL), to study the effect of three oral formulations of a Lactobacillus salivarius strain (powder, capsule and sustained-release tablet) on its viability and interactions with gut microbiota. In the TIM-1 stomach, no or low numbers of bacteria were respectively released from the capsule and tablet, confirming their gastro-resistance. The capsule was disintegrated in the jejunum on average 76 min after administration while the core of sustained-release tablet was still intact at the end of digestion. Viability in TIM-1 was significantly influenced by the galenic form with survival percentages of 0.003±0.004%, 2.8±0.6% and 17.0±1.8% (n=3) for powder, capsule and tablet, respectively. In the ARCOL, the survival of the strain tended to be higher in the post-treatment phase with the tablet compared to capsule, but gut microbiota composition and activity were not differently modulated by the two formulations. In conclusion, the sustained-release tablet emerged as the formulation that most effectively preserved viability of the tested strain during GI passage. This study highlights the usefulness of in vitro gut models for the pre-screening of probiotic pharmaceutical forms. Their use could also easily be extended to the evaluation of the effects of food matrices and age on probiotic survival and activity during GI transit.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 0 | 0 | 0 |
| Gesamttextansichten | 633 | 217 | 27 |
| PDF-Downloads | 540 | 179 | 15 |
